OptiNose AS

99 articles with OptiNose AS

• OptiNose AS Announces Positive Results Of Phase III Trial For OPN-375

  6/24/2015

• OptiNose AS To Present At Innovations In Healthcare Executive Forum

  3/30/2015

• OptiNose AS To Present At Nasal And Respiratory Drug Delivery Conferences

  3/19/2015

• OptiNose AS To Present At The 35th Annual Cowen and Company Healthcare Conference

  2/23/2015

• OptiNose AS Announces Publication Of Pivotal Phase 3 Results For Investigational Migraine Treatment Developed By Optinose Using Bi-Directional™ Breath Powered™ Technology

  10/31/2014

• OptiNose AS Completes Series C-1 Financing

  8/4/2014

• OptiNose AS Expands Senior Management Team With Three Key Appointments In Core Business Areas Of Operations, Regulatory Affairs And Commercialization

  6/12/2014

• OptiNose AS Presents Positive Results From Phase 3 COMPASS Study

  6/10/2014

• OptiNose AS Announces FDA Acceptance Of New Drug Application For AVP-825 For The Acute Treatment Of Migraine

  3/27/2014

• OptiNose AS to Present Data Highlighting New Migraine Treatment at International Headache Congress

  6/28/2013

• OptiNose AS Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device

  2/9/2012

• OptiNose AS Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology

  2/3/2012

• OptiNose AS Selects BioClinica, Inc.'s Trident IWR, Optimizer and Imaging Core Lab Solutions

  9/8/2011

• OptiNose AS Standardizes on Medidata Solutions, Inc. Rave Clinical Technology

  8/30/2011

• OptiNose AS Bi-Directional Drug Delivery Technology Wins Innovation Award for Potential Benefits of Nose to Brain Application

  5/23/2011

• OptiNose AS Receives Nearly $489,000 Grant Award under U.S. Government Qualifying Therapeutic Discovery Project Program

  11/3/2010

• Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose AS's Novel Drug Delivery Technology

  10/28/2010

• OptiNose AS Announces Publication of Positive Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology

  8/10/2010

• Avista Capital Partners Commits $48.5 Million to OptiNose AS to Develop an Innovative Nasal Drug Delivery Technology Slated to Begin Phase III Trials

  6/8/2010